Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | GPR183 | P32249 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | CFD | P00746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22854230 | 0.93 | HRH4 (0.40) | HRH4KMT2AGPR183MEN1 | |
| SCHEMBL22854158 | 0.91 | HRH4 (0.48) | HRH4KMT2ANPC1RAB9AMEN1 | |
| SCHEMBL22854139 | 0.91 | HRH4 (0.49) | HRH4KMT2AGPR183MEN1HRH1 | |
| SCHEMBL22831725 | 0.89 | HRH4 (0.46) | HRH4HRH3 | |
| SCHEMBL22854157 | 0.89 | HRH4 (0.50) | HRH4KMT2ANPC1RAB9AMEN1 | |
| SCHEMBL22854166 | 0.86 | DRD2 (0.40) | HRH4KMT2AGPR183NPC1RAB9A | |
| SCHEMBL22854231 | 0.86 | HRH4 (0.49) | HRH4KMT2AGPR183MEN1HRH1 | |
| SCHEMBL22854142 | 0.85 | HRH4 (0.50) | HRH4KMT2AMEN1CFD | |
| SCHEMBL22854236 | 0.85 | HRH4 (0.49) | HRH4MAPT | |
| SCHEMBL22854138 | 0.84 | NPC1 (0.50) | HRH4KMT2ANPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200407365-A1 | INDOLE-2-CARBONYL COMPOUNDS AND THEIR USE FOR THE TREATMENT OF HEPATITIS B | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200407365-A1 | INDOLE-2-CARBONYL COMPOUNDS AND THEIR USE FOR THE TREATMENT OF HEPATITIS B | IDO2, IDO1, SLC10A1 | HRH4 1032/4885KMT2A 2114/4885GPR183 865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.